MedTech Industry Dynamics
MedTech Industry Dynamics
Abbott has received CE Mark for the Amulet 360 Left Atrial Appendage (LAA) Occluder, a next-generation device designed to reduce stroke risk in patients with non-valvular atrial fibrillation, featuring design updates for improved conformability and sealing.
Read MoreRoche has received FDA clearance for its Elecsys pTau217 blood test, the first and only FDA-cleared single-biomarker test supporting both rule-in and rule-out assessment of amyloid pathology. Quest Diagnostics and Labcorp will offer the test to clinicians nationwide.
Read MoreC2N Diagnostics has received FDA clearance for its PrecivityAD2 blood test, the first Alzheimer’s diagnostic aid cleared for use in symptomatic adults aged 40 and older, delivering high diagnostic performance to help clinicians rule in or rule out clinical Alzheimer’s disease.
Read MoreMaxQ Medical закрыла раунд финансирования серии A на сумму 31,5 миллиона долларов под руководством Atlantic Blue Ventures, S3 Ventures и Olympus Innovation Ventures для продвижения своей трансуретральной системы визуализации и терапии для доброкачественной гиперплазии предстательной железы и рака простаты.
Read MoreEnginprime Medical has closed a $12 million Series A financing round led exclusively by Qiming Venture Partners to fund the China registration trial for its OpusOne percutaneous ventricular assist device and support early-stage clinical development globally.
Read MoreiRhythm has entered into a definitive agreement to acquire VitalConnect for approximately $287.5 million, expanding its cardiac monitoring platform with mobile cardiac telemetry, multi-vitals monitoring, and hospital-to-home care capabilities.
Read MoreSiemens Healthineers’ innovation center team visited Sinovation Medical’s Beijing headquarters for the second time in two months, advancing technical discussions on MR-guided laser ablation, surgical robotics, and a mobile CT integration for emergency scenarios.
Read MoreKKR has agreed to acquire Integer Holdings Corporation in an all-cash transaction valued at approximately $5.7 billion, with Integer stockholders receiving $127 per share, while the company also reported second quarter sales of $464 million.
Read MoreCoreMap закрыл переподписанный раунд финансирования серии C на сумму 37 миллионов долларов под руководством Medtronic для ускорения разработки и выхода на рынок своей платформы картирования фибрилляции предсердий нового поколения.
Read MoreXeltis привлек дополнительные 20,5 миллиона евро в новом раунде финансирования под руководством Horizon 3 Healthcare, при участии EIC, Invest-NL и существующих акционеров, для продвижения своего решения для сосудистого доступа aXess через ключевые американские исследования и подготовки к подаче заявки в FDA и коммерческому запуску.
Read More
